Waste mitigation in clinical trials: How to optimise your drug inventories
Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here

Waste mitigation in clinical trials: How to optimise your drug inventories

01 Jul 2021

Sponsored by Aposave Sponsored by Visit Company
Waste mitigation in clinical trials: How to optimise your drug inventories

Clinical trials require the holistic management of a lot of moving parts and increasingly so, as more and more clinical trials go global. It is no wonder then that approximately 70% of these trials are outsourced to Contract Research Organisations (CROs) to optimise every stage of the process.

 If there is one thing that indicates that a clinical trial is not running optimally, it is waste. Wasted time, wasted research, and wasted medicine also mean wasted money, an immediate deterrent for potential shareholders and investors.

 According to Ian Hoban, business development director for Healthcare and Pharma Services company Aposave: “Anecdotally, we’re told between 20-25% of drugs are wasted in comparative clinical trials. We also know that COVID-19 has impacted the amount of destruction of medicines because many projects have been stalled, meaning that inventory that’s been built in advance of the delay now has compromised expiry dates.”

 While the global pandemic has had the most notable effect on the industry, drastically changing the way that trials operate, there have always been a myriad of factors that trial sponsors have needed to consider in order to optimise their inventory and reduce the risk of waste.

 “There’s often a disconnect between what was initially thought to be needed and what is actually needed at any given time during the life of the clinical trial,” Hoban explains. “It’s not just about avoiding destruction of surplus/expired stock. On the flip side, if companies source insufficient stock to allow for risks at certain pressure points in the supply chain, lack of provision of extra contingency stock can easily lead to insufficient stock availability to treat some of the patients that have been recruited.

 “So, it’s a fine balancing act to ensure inventory levels are optimised to avoid both excessive surplus stock build-up and potential stock outages which need to be reviewed dynamically. Medicines sourced for clinical trials have got a finite shelf life. So, if something like a three-month delay to start the trial occurs, the longer-term viability of the stock will be compromised depending on the profile of the comparator being sourced.

 “Some drugs have a 36-month shelf life, so you can confidently buy all the inventory you need for a two year study and you are probably not going to have any issues. But with other comparators, even if you buy direct from the manufacturer, you may only get a 15-month shelf life at best. So, a ‘one size fits all’ approach should never be taken.”

 Several factors can delay trials such as the global footprint of the trial, issues with recruitment, and obstacles with regulations. Often, the more regions that are involved in a single trial, the higher the number of interfaces. This means that trials will invest in more surplus stock to cover the risk for each of those potential hurdles. This not only increases the chance of wasted stock, but also makes visibility more complicated if stock is being stored in multiple locations.

 Aposave can help clinical trial sponsors to optimise inventory management and reduce the risk of waste with its bespoke trial planning solutions.

 “It’s the nature of a holistic approach to the whole clinical study design that waste is reduced,” Hoban explains. “Typically, there is a lot of focus on where we want the patients recruited for the trial coming from Big Pharma, so we can estimate how many patients we can recruit in a timescale. This means that we know the amount of stock required before we replenish, so that natural process can start quite early.

 “We don’t leave these things to assumption, it’s constant reviewing of all the elements of the trial that impact when patients are likely to be available so that the correct amount of inventory is planned to be in the right place at the right time so they can get treated.”

 Aposave can help clients procure multiple batches of medicines in agreed quantities, along with the necessary documentation. As part of the Abacus Medicine Group the company has extensive supply networks, and its advisory services help clients to design a solution that means only minimal product gets destroyed.

 This includes a methodology that helps customers to recycle surplus products through parent company Abacus Medicine. Aposave can support companies with short-dated stock and buy it back from them and then repackage the product and sell it to their hospital customers.

 Aposave’s unique industry position means they can work with clients from start to finish, helping to ensure that trials have the right amount of product at the right time.

 For more information about how Aposave could save your company money and provide innovative clinical trial solutions, download the whitepaper below.

Free Case Study

Drastically reducing the risk of unplanned comparator clinical trial costs

Comparator trials that weigh the benefits of bringing new drugs to market with the efficacy of existing therapies can be costly and unwieldy – particularly as the new therapy is usually sourced at phases II and III, leaving unused, expensive inventory for sponsors to deal with.

With patient recruitment problems also being a well-documented issue associated with clinical trials, this may also lead to unplanned build-up of expiry date issues with trial comparator inventory.

So, what’s the best solution? In this whitepaper, clinical trial services company Aposave explores the challenges and solutions faced by clients engaged in these trials. To learn more about how you can ethically and cost-effectively deal with these issues, download the free whitepaper below.

By clicking the “Submit” button above, you accept the Terms & Conditions and acknowledge that your data will be used as described in the Aposave Privacy Policy.

We will also collect and use the information you provide for carefully considered and specific purposes, where we believe we have a legitimate interest in doing so, for example to send you communications about similar products and services we offer. We will always give you an option to opt out of any future communications from us. You can find out more about our legitimate interest activity in our privacy policy here. ‘We’ includes Verdict Media Limited and other GlobalData brands as detailed here.